Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Projects from Affini-T, Bolt, Chimeric and Alentis, all hitting novel targets, as well as one from A2 using an old one, are set for first clinical trial entry.
Front-line phase 3 plans take shape, as the company claims a new success, this time in pancreatic cancer.
The companies have all switched to improved fourth-generation EGFR projects in lung cancer, a fact that likely shows how competitive this field has become.
A work-stretched US FDA has several key approval application still to review by the end of 2023.
As Tropion-Breast01 is toplined positive Astra ensures the markets know that overall survival isn’t a washout.
BeiGene regains rights to tislelizumab as another oncology asset blows up for Novartis.